Skip to search formSkip to main contentSkip to account menu

Anti-KIR3DL2 Monoclonal Antibody IPH4102

Known as: Anti-KIR3DL2 mAb IPH4102, IPH4102 
A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma
ABSTRACT Introduction: Therapeutic options for mycosis fungoides and Sézary syndrome include a variety of immunomodulatory… 
2018
2018
IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial
Aims: Sezary Syndrome (SS) is the most aggressive form of cutaneous T cell lymphoma (CTCL), characterized with high blood… 
2018
2018
IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
2017
2017
New Targeted Treatments for Cutaneous T-cell Lymphomas
Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at… 
2016
2016
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large‐cell lymphoma
KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8+ T cells, is aberrantly expressed in… 
2016
2016
First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and…
KIR3DL2 is expressed in all subtypes of cutaneous T-cell lymphomas (CTCL), irrespective of clinical stage, with the highest… 
2015
2015
A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies
Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases… 
Highly Cited
2014
Highly Cited
2014
IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
Advanced cutaneous T-cell lymphoma (CTCL) remains an unmet medical need, which lacks effective targeted therapies. In this study… 
2014
2014
IPH4102, un anticorps anti-KIR3DL2 humanisé, a une activité antitumorale ciblée in vivo et ex-vivo contre les lymphomes T cutanés
1999
1999
차세대 인터넷 IP 프로토콜 기술
Marseille, November 10, 2016 Innate Pharma SA (the “Company” Euronext Paris: FR0010331421 – IPH) today announces that the Company… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)